Japan`s Drug Committee Approves Bristol-Myers Squibb SGLT-2 Inhibitor
This article was originally published in PharmAsia News
Executive Summary
Japan Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) First Committee on Drugs gave the green light for Bristol-Myers Squib SGLT-2 inhibitor Fosyga (dapagliflozin), also known as Farxiga in the United States.